Tecelra is the first engineered cell therapy for the treatment of certain patients with advanced synovial sarcoma. One year ...
ALL is the most common childhood cancer, and cases are rising. Find out why this trend is paired with a remarkable 90% survival rate, and what public health action is needed next.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback